China Orthopedic Instrument Industry Report, 2013-2015
Benefiting from aging of population, consumption upgrade and policy support, China's orthopedic instrument industry has seen rapid development over the years, with total market size rising from 3.28 billion yuan in 2006 to 9.85 billion yuan in 2012.
Trauma products, spine products and joint products constitute the three major market segments of Chinese orthopedic instrument industry. In 2012, the three principal products accounted for an aggregate market share of about 82.2%, of which, trauma products showed the highest, approximately 35.5%, with market size up 18.24% YoY; spine and joint products ranked second (up 12.6% YoY) and third (up 12.4% YoY), respectively.
In recent years, along with the increasing investment of foreign-funded enterprises in China, the trend of foreign monopoly has been more evident. After the acquisition of Synthes in 2012, Johnson & Johnson has turned into the largest company in China's orthopedic instrument market, with market share of both trauma and spine products occupying the first place.
In November 2012, Medtronic purchased KangHui Medical for $816 million, thus making an important step in Chinese orthopedic instrument market localization. Compared with Medtronic's high-end positioning, affordable KangHui products can help Medtronic expand low- and medium-end markets in emerging countries and regions (including China). In 2012, Medtronic (including KangHui Medical) occupied 15.9% of China's spine market.
Stryker is a world-renowned orthopedic instrument enterprise, and its joint products account for about 20% of global market share. In January 2013, Stryker acquired Trauson Holdings for $764 million, and in virtue of the latter’s R&D and manufacturing capacity and distribution network advantages further expanded its market share in China, expected to occupy 8%-10% of China's orthopedic market in 2013.
Relying on powerful R&D strength and mature distribution network, Weigao has already become the largest local supplier of orthopedic devices in China. In 2012, its orthopedic device business achieved revenue of 223 million yuan, and trauma equipment products occupied market share of 5.1% or so.
In future, the Chinese orthopedic instrument market will encounter more fierce competition, in which small companies due to low R&D level, insufficient production capacity and non-standard quality control tend to be gradually eliminated, and the market will be further concentrated in industry magnates with superb financial and technical strength.
China Orthopedic Instrument Industry Report, 2013-2015 of ResearchInChina mainly covers the followings:
- Overview, market structure and development prospect, etc. of global orthopedic instrument industry;
- Market structure, competition pattern, barriers to entry, import & export, etc. of China orthopedic instrument industry;
- Development environment (including policy environment, development prospects as well as development of upstream and downstream industries) for China orthopedic instrument industry;
- Operating conditions, etc. of 12 orthopedic instrument companies (including Johnson & Johnson, Medtronic, Stryker, Weigao, Shanghai Kinetic, Beijing AKEC Medical, United Orthopedic Corporation, etc.) in China.
China Orthopedic Instrument Industry Report, 2013-2015
Related reports :
- Investigation Report on China Fat Emulsion Market, 2010-2019
As an emulsion of soy bean oil, egg phospholipids and glycerin, fat emulsion injection provides essential fatty acids for people who are unable to get nutrition via an oral diet. The concept of fat emulsion dated back to the 1960s when hospi...
- Investigation Report on China Ornidazole Market, 2010-2019
As the third generation of nitroimidazole antibiotics, ornidazole is used to combat anaerobic bacterial and parasitic infections. It inhibits nucleic acid synthesis by disrupting the DNA of microbial cells. Compared with metronidazole and tinidazo...
- Investigation Report on China Ioversol Market, 2010-2019
As a non-ionic contrast medium, ioversol featuring low toxicity and few effects is mainly used to enhance the contrast of blood vessels in medical imaging. Containing iodine, ioversol works based on x-ray attenuation. Contrast medium is co...
- Investigation Report on China Dydrogesterone Market, 2010-2019
According to statistics, over 90% of Chinese adult women suffer from different kinds of gynecological conditions to different degrees. And for married urban women, the TOP5 gynecological disorders are genital tract infections (42.9%), menstrual di...
- Investigation Report on China Propofol Market, 2010-2019
As a short-acting amnestic agent, propofol features rapid recovery and few adverse effects. And it has been widely used in the maintenance of general anesthesia and sedation for critically ill patients. Generally used together with spinal anesthes...
- Investigation Report on China Remifentanil Market, 2009-2018
As a new generation of opiates, remifentanil (remifentanil hydrochloride) is an ideal intravenous anesthetic with short onset and good controllability. Remifentanil hydrochloride injection is a narcotic used for the maintenance of general anesthes...
- Investigation Report on China Cinepazide Market, 2010-2019
As a new generation of piperazine, cinepazide(cinepazide maleate) has been widely used in Europe and Japan. As calcium channel blocker, cinepazide can stop calcium from entering vascular smooth muscle cell and relax smooth muscle of cerebral vesse...
- Investigation Report on China Deproteinized Calf Blood Extract Market, 2010-2019
As a drug improving energy metabolism, deproteinized calf blood extract has received wide attention due to its efficacy in nervous system. Currently, it is mainly used to treat brain disease, nervous system disease, vascular disease, ulcer, burn, ...
- Investigation Report on China Cattle Encephalon Glycoside and Ignotin Market, 2010-2019
According to WHO, such noncommunicable diseases as cardiovascular disease, cancer, chronic respiratory disease, diabetes have become severe threats to human health in the 21st century. According to the Report on Cardiovascular Diseases in China (2...
- Investigation Report on China Alteplase Market, 2010-2019
As the second generation of thrombolytic, anticoagulant factor alteplase can dissolve blood clots by activating plasminogen and then dissolving fibrin. For acute myocardial infarction, alteplase given intravenously can unclog coronary artery. ...